Pharmacotherapy for Alzheimer’s Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 545
Special Issue Editor
Interests: neuroscience; Alzheimer’s disease; in vivo studies; drug development; cannabinoid-based pharmaceuticals; repurposing current therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A large body of studies highlight that Alzheimer’s disease (AD), described as a complex neurodegenerative disorder with a multilayered nature leading to a progressive decline in cognitive function and irreversible neuronal loss, continues to present a significant and escalating challenge to global health. As the frequency of cases rises and conventional pharmaceutical treatments, which primarily alleviate symptoms and come with numerous side effects, continue to exhibit a high rate of ineffectiveness, there arises a pressing demand for alternative approaches. Despite extensive knowledge on the molecular basis of AD, advancements in developing therapies that truly modify the progression of the disease have proven to be elusive. The ability of the editing system tools, repurposing current therapeutics or utilizing multi-target-directed ligands, presents a promising opportunity to elucidate the fundamental mechanisms driving AD pathogenesis and to discover new therapeutic pathways. This strategy has the potential to facilitate the identification of target molecules and the development of innovative preclinical disease models, thus providing hopeful prospects for therapeutic intervention.
Authors are invited to submit original research and review articles highlighting recent findings in the pharmacotherapy of Alzheimer’s disease. These includes, but are not limited to, novel molecular mechanisms and potential therapeutic targets, developing or repurposing drugs with the ability to target multiple disease features or exploring the risks and benefits of cannabinoid-based drugs.
Dr. Gabriela Dumitrița Stanciu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- pharmacotherapy
- therapeutic editing tools
- repurposing existing therapeutics
- multi-target-directed ligands
- preclinical studies
- neurodegeneration
- drug development
- neuroprotection
- cannabinoid-based pharmaceuticals
- single-molecule drugs or whole-plant extracts of Cannabis sativa L.
